Profil
Bosko Djordjevic is Founder of Pre-Merger Lipid Sciences.
He was a Director of Lipid Sciences, Inc. from March 2004 to October 2, 2008 and served as Chairman of the Compensation Committee and a Member of the Executive, Nominating and Corporate Governance and Audit Committees.
Mr. Djordjevic was a Director of Pre-Merger Lipid Sciences from January 2000 to November 2000.
Ehemalige bekannte Positionen von Bosko Djordjevic
| Unternehmen | Position | Ende |
|---|---|---|
Lipid Sciences, Inc.
 Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | Direktor/Vorstandsmitglied | 02.10.2008 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | Commercial Services |
